GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Monte Rosa Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.66+0.92 (+9.45%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Monte Rosa Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Market Cap | $909.44M | $164.85M |
| Enterprise Value | $288.34M | $87.06M |
| PS Ratio | 31.66 | 3.60 |
| PB Ratio | 1.87 | 2.03 |
| P/TBV Ratio | 1.87 | 2.31 |
Enterprise value
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10.04 | 2.43 |
Income (trailing twelve months)
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Revenue | $28.73M | $57.94M |
| Operating Income | -$181.85M | -$21.44M |
| Pretax Income | -$163.97M | -$14.45M |
| Net Income | -$161.09M | -$22.46M |
| EBITDA | -$181.85M | -$16.91M |
| EPS (Diluted) | -$1.76 | -$0.83 |
Margins
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -633.0% | -44.5% |
| Pretax Margin | -570.8% | -13.0% |
| Profit Margin | -560.8% | -39.2% |
| EBITDA Margin | -633.0% | -31.3% |
| FCF Margin | -111.7% | -8.85% |
Returns
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -42.7% | -53.1% |
| Return on Assets (ROA) | -30.7% | -41.0% |
| Return on Capital Employed (ROCE) | -28.8% | -37.8% |
Growth
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -83.9% | 6.01% |
| Net Income Growth (YoY) | -766.5% | -37.7% |
| EPS Growth (YoY) | -706.9% | -29.2% |
| FCF Growth (YoY) | -234.5% | 2.34% |
Balance sheet
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $621.10M | $62.42M |
| Net Cash (Debt) | $621.10M | $15.68M |
| Net Cash Per Share | $7.28 | $0.66 |
| Equity (Book Value) | $487.28M | $48.79M |
| Book Value Per Share | $5.71 | $1.36 |
| Tangible Book Value | $487.28M | $23.06M |
| Working Capital | $571.75M | $75.77M |
Financial position
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.58 | 3.30 |
| Quick Ratio | 10.41 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$24.07M | -$12.35M |
| Capital Expenditures | -$8.01M | -$1.06M |
| Free Cash Flow | -$32.08M | -$20.28M |
| FCF Per Share | -$0.38 | -$0.42 |
Efficiency
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.38 |
| Revenue Per Employee | $191.51K | $398.96K |
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 150 | 74 |
Dividends and yields
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -17.7% | -22.7% |
| FCF Yield | -3.53% | -9.07% |
Shares
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 85,313,400 | 58,179,650 |
| Shares Change (YoY) | 11.5% | 11.1% |
| Shares Change (QoQ) | 1.07% | 0.54% |
| Float | 75,479,600 | 49,173,100 |
| Shares Held by Insiders | 11.5% | 11.6% |
| Shares Held by Institutions | 109.4% | 59.4% |
Taxes
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$2.86M | $91.50K |
Scores
| Measure | Monte Rosa Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.70 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Monte Rosa Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.